Do bisphosphonates and RANKL inhibitors alter the progression of coronary artery calcification? A systematic review =================================================================================================================== * Samantha Louise Saunders * Kanika Chaudhri * Nathan Scott McOrist * Karen Gladysz * Sonali R Gnanenthiran * Grant Shalaby ## Abstract **Objectives** To determine whether bisphosphonates and NF-κB ligand (RANKL) inhibitors delay coronary artery calcification (CAC). **Design** A systematic review was conducted. **Data sources** MEDLINE, EMBASE and CENTRAL. **Eligibility criteria** Longitudinal studies investigating CAC progression in adults (>18 years) taking either a bisphosphonate or denosumab compared with those who did not. **Data extraction and synthesis** Study and participant characteristics, and primary outcome ( ∆ CAC from baseline to follow-up) were extracted. The Risk Of Bias In Non-Randomised Studies-of Interventions (ROBINS-I) and Risk-of-Bias Tool for Randomised Trials (RoB2) tools were used to assess the risk of bias for observational and randomised controlled trials (RCTs), respectively. Outcome measures were reported. **Results** Four observational studies and one RCT (n=377) were included. Three studies solely reported the effect of bisphosphonates on ∆ CAC; one study (n=56) demonstrated a statistically significant CAC reduction in the intervention group (−372 mm3/year) compared with control (+159 mm3/year) (p<0.01). One study (n=14) demonstrated a difference in ∆ CAC between intervention (+880 mm3/year) versus control (+2220 mm3/year), however, no p value comparing groups was reported. One study (n=115) found no statistically significant difference between intervention and control. One study (n=42) exclusively investigated the effect of RANKL on ∆ CAC; there was a statistically significant reduction in CAC at 6-month follow-up between intervention (−133±124 modified Agatston unit (AU)) and control (+188±72 modified AU), p=0.03. One study (n=150) compared both bisphosphonates and denosumab to control and found no statistically significant difference between either intervention group and control over 24 months. Meta-analysis was not performed due to limited, heterogeneous studies. **Conclusions** There is insufficient evidence supporting the correlation between bisphosphonate or RANKL inhibitor use and CAC progression. Further research is warranted. * Coronary heart disease * Cardiovascular Disease * Calcium & bone * Lipid disorders * Diagnostic Imaging * Cardiovascular imaging ### STRENGTHS AND LIMITATIONS OF THIS STUDY * Studies included in the review were not limited to study design; this means that most potentially relevant studies were not missed in synthesising the literature on this topic. * Three large databases were systematically searched from inception to the time of the first submission of the review, and therefore, it is unlikely that relevant articles were missed for potential inclusion in the study. * Meta-analysis was unable to be performed in view of the small number of heterogeneous papers eligible for inclusion in the review. * The review is limited to studies which have been published. * The review is limited to studies published in the English language. ## Introduction Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide, accounting for 17.9 million deaths, annually.1 Coronary artery calcium (CAC) is a highly specific marker of established atherosclerotic plaques2 and is attained from axial non-contrast computed tomography (CT) slices. It is reported as the modified Agatston score, which is expressed as Agatston units (AUs).3 CAC scoring has been shown to predict the risk of future cardiovascular events in asymptomatic patients.4 Bisphosphonates and NF-κB ligand (RANKL) inhibitors are medications typically indicated for the management of osteoporosis. Evidence suggests that there may be a role for their use in reducing the progression of CAD, via their effects on plaque formation.5 6 Bisphosphonates have been shown to inhibit the crucial regulatory enzyme, farnesyl pyrophosphate synthase in the mevalonic acid pathway, which is implicated in both bone and lipid metabolism, and thus alter the progression of ectopic calcification.5 6 RANKL inhibitors, including denosumab, interfere with the glycoprotein, osteoprotegerin and other signalling pathways, again involved in lipid metabolism. Furthermore, calcified plaques shown on unenhanced CT images are much alike to bone itself. Together, this information suggests that the fundamental underlying biochemical pathways involved in bone formation and vascular calcification are likely shared. The implication of such could mean an additional therapeutic target in managing CAD, which is relevant in those for whom traditional cardiovascular therapies are no longer sufficient to control disease progression. Etidronate is one bisphosphonate whose effects upon CAD have been studied. Three studies have shown that etidronate may delay the progression of CAD, which has been measured through the surrogate endpoints of aortic calcification scores, CAC scores and carotid artery intima–media thickness, respectively.7–9 The effects of nitrogen-containing bisphosphonates (NC-BPs), however, on vascular calcification are contradictory in the literature. Some randomised controlled trials (RCTs) have suggested that alendronate, the most studied of the NC-BPs, is protective against CAD progression, again through a reduction in carotid intima–media thickness,10 11 and total volume of vascular calcification.12 13 These trials all contained less than 75 patients, with effects on vascular calcification largely observed in patients with chronic kidney disease (CKD) or in those receiving haemodialysis, only. Meanwhile, one small pilot study by Hill *et al,* showed that there was no significant difference in CAC progression between those receiving alendronate and placebo.14 There is very limited evidence assessing the role of the RANKL inhibitor, denosumab, in the progression of vascular calcification. A recent RCT revealed that after 12-month follow-up there was no significant difference in CAC and carotid artery intima–media thickness between those on denosumab versus control.15 Conversely, another study demonstrated that denosumab may indeed suppress the progression of CAC,16 although this was restricted to patients with secondary hyperparathyroidism. These conflicting data highlight the need for consolidation of the literature by means of a systematic review. Over the last decade, two systematic reviews have been performed on similar topics. The first investigated the effects of bisphosphonates on multiple vessels, including the carotids, coronaries and aorta in patients undergoing haemodialysis.17 However, the review published 10 years ago included only two papers which investigated the effects of etidronate, on CAC specifically, in a highly selected population group, limiting the generalisability of the findings. The second, more recent study was also limited by the inclusion of small sample size studies and a short duration of follow-up. Additionally, no systematic review to our knowledge has explored the impact of denosumab on vascular calcification. The primary aim of the systematic review was to evaluate the relationship between the use of bisphosphonates and the RANKL inhibitor, denosumab, with CAC. We hypothesised that there would be an inverse relationship between bisphosphonate and denosumab use and CAC. Furthermore, this review aimed to assess the relationship between these medications and aortic and carotid calcification through its secondary outcomes. If a true association between bisphosphonate or RANKL inhibitor use and CAC can be established in a large, diverse cohort of patients, it may warrant their use in those with elevated CAC. This could prove vital in both the primary and secondary prevention of cardiovascular events in those who are at high risk of severe complications. ## Methods The methods of this review have been published as a protocol18 and are outlined in brief (please see online supplemental file 1). ### Supplementary data [[bmjopen-2024-084516supp001.pdf]](pending:yes) ### Eligibility criteria Definitions as per Patient-Intervention-Comparator-Outcome-Duration (PICO-D) were adapted for the purpose of this review. An article was included in the study if it met the PICO-D criteria as outlined in table 1. View this table: [Table 1](http://bmjopen.bmj.com/content/14/9/e084516/T1) Table 1 PICO-D criteria for inclusion of studies in the review ### Search strategy A structured search of MEDLINE (inception – present), Embase (inception – present) and the Cochrane Central Register of Controlled Trials (CENTRAL) was performed. Citation lists of any relevant papers found were handsearched to identify further pertinent articles. The search strategy was developed by a medical librarian (online supplemental file 2), with search syntax altered as appropriate according to each database’s subject headings and thesaurus. Search keywords included CAC, bisphosphonates, RANKL inhibitors and denosumab. ### Supplementary data [[bmjopen-2024-084516supp002.pdf]](pending:yes) ### Study selection The articles yielded by the search were screened by title and abstract against our inclusion and exclusion criteria. Following initial title/abstract screening, the full text of potentially eligible papers was then appraised for final inclusion in the systematic review. A third reviewer adjudicated if there was a discrepancy in the inclusion status of any study. This process was documented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. ### Data collection Two independent reviewers (NSM and KG) extracted data items from included reviews as per a standardised data extraction form (online supplemental file 3). Extracted data included study design, country and setting, aims and objectives, study population, intervention, control, outcomes, risk of bias and demographical data. ### Supplementary data [[bmjopen-2024-084516supp003.xlsx]](pending:yes) ### Outcomes The primary outcome extracted was the difference in CAC from baseline to follow-up in patients who used either a bisphosphonate or denosumab compared with those who did not. The secondary outcomes of the review were carotid artery intima–media thickness and aortic calcification, both measured in cubic millimetres, in those using either a bisphosphonate or denosumab compared with placebo. ### Risk of bias Risk of bias was assessed using the ROBINS-I tool19 for non-randomised studies and the RoB2 tool20 for RCTs. The studies were graded as low, moderate or high for risk of bias per criterion and for overall bias. ### Data synthesis and analysis Studies were included if they fulfilled the eligibility criteria. Data were presented narratively and complemented with tables and figures as appropriate. The outcomes of each study were extracted, with their effect size measured by OR or relative risk and their corresponding 95% CIs, where available. The statistical significance reported by their p values was also collected where available, as stated by the study authors. Lastly, the main conclusions drawn by the authors were extracted. Meta-analysis was not performed due to the heterogeneity of included studies, which was assessed per the definition reported in the Cochrane Handbook for Systematic Reviews of Interventions.21 Heterogeneity in the included studies was demonstrated in their clinical variation that is, diverse populations studied with variations in treatment type and dose, and methodological variation as evidenced by study design (prospective observational vs RCT) and variance in reporting of the outcome measure (CAC reported in cubic millimetres vs AU), the latter of which most markedly precluded meta-analysis. ### Patient and public involvement None. ## Results ### Study inclusion 112 potentially relevant articles were identified from a systematic search of the literature, of which five met the review inclusion criteria (see figure 1); four observational studies and one RCT were included with a total of 377 patients.7 8 14 16 22 Individual study characteristics are documented in table 2. Three studies reported outcomes pertaining to bisphosphonate use, one on denosumab use and one study investigated the use of both. ![Figure 1](http://bmjopen.bmj.com/https://bmjopen.bmj.com/content/bmjopen/14/9/e084516/F1.medium.gif) [Figure 1](http://bmjopen.bmj.com/content/14/9/e084516/F1) Figure 1 PRISMA diagram demonstrating how studies were included in the review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses; RANKL, NF-κB ligand. View this table: [Table 2](http://bmjopen.bmj.com/content/14/9/e084516/T2) Table 2 Study characteristics ### Risk of bias in included studies A summary of the risk of bias in each study can be found in tables 3 and 4 for observational studies and RCTs, respectively. Low overall risk inferred a low risk in each criterion. Moderate overall risk was determined by moderate risk in at least one criterion, without high risk in any criterion. High overall risk was determined by high risk in at least one criterion. View this table: [Table 3](http://bmjopen.bmj.com/content/14/9/e084516/T3) Table 3 Risk of bias in included studies for observational studies and randomised controlled trials View this table: [Table 4](http://bmjopen.bmj.com/content/14/9/e084516/T4) Table 4 Risk of bias in included studies for randomised controlled trials ### Demographical data and population Demographical outcomes included age, sex, presence of hypertension, diabetes, dyslipidaemia, CKD and smoking status (see table 5). There was a large proportion of patients who had end-stage renal disease on dialysis (three studies, n=112) and osteoporosis (one study, n=115). One study did not report any demographical baseline characteristics of participants except for age. One study reported only on age and sex. The remaining studies reported on each of the aforementioned characteristics. No studies reported on family history of CAD, and consequently, these data are not included in table 5. View this table: [Table 5](http://bmjopen.bmj.com/content/14/9/e084516/T5) Table 5 Baseline characteristics ### Primary outcomes #### Bisphosphonate use Nitta *et al* (n=56) reported the action of the bisphosphonate, etidronate on CAC progression and demonstrated a statistically significant reduction in CAC (−372 mm3 over 12 months) compared with patients not taking etidronate (+159 mm3 over 12 months) (p<0.01). Ariyoshi *et al* (n=14) who also reported the effect of etidronate use on CAC progression demonstrated a difference between intervention (+880 mm3 over 12 months) vs control (+2220 mm3 over 12 months), however, no p value directly comparing the two groups was reported. A third study by Hill *et al* (n=115) found no statistically significant difference between intervention with the bisphosphonate, alendronate (+2.4 modified AU per month) and control (+3.1 modified AU per month), p=0.46. Pawade *et al* (alendronate use, n=51; control n=50) similarly found no statistically significant difference between alendronate use (+326 (138–813) modified AU over 24 months) and control (+354 (76–675) modified AU over 24 months), p=0.49. #### Denosumab use Chen *et al* (n=42) investigated denosumab use on CAC progression and found a statistically significant reduction at 6-month follow-up between intervention (−133±124 modified AU) and control (+188±72 modified AU), p=0.03. Pawade *et al* (denosumab use, n=49; control, n=50) found no statistically significant difference between denosumab use (+343 (198–804) modified AU) vs control (+354 (76–675)) over a 24-month period, p=0.41. Primary outcome data can be seen in table 6. Meta-analysis was not performed due to limited, heterogeneous studies as previously discussed. View this table: [Table 6](http://bmjopen.bmj.com/content/14/9/e084516/T6) Table 6 Primary Outcomes ### Secondary outcomes #### Aortic calcification Ariyoshi *et al* (n=14) reported the progression of aortic calcification in those receiving etidronic acid versus those who were not.7 Aortic calcification was found to improve in the intervention group (–64.1% (–6.5 to –50.1)) versus in the control group (+130% (2.1–414%)) over a 12-month period (p=0.006). #### Carotid artery calcification None of the included studies reported on carotid artery intima–media thickness in those using either a bisphosphonate or denosumab compared with a placebo. ## Discussion Optimisation of risk factors remains challenging for many patients with moderate to severe CAD, and subsequently, the search for additional therapeutic targets is needed. Our review collected data from observational studies and a single RCT and is the first to summarise the evidence exploring the role of bisphosphonates and RANKL inhibitors, respectively, in the progression of CAD as objectively measured via CAC. ### Bisphosphonates and CAC Four studies investigated the action of bisphosphonates on CAC progression. Nitta *et al*’s study was the only study to report a statistically significant reduction in CAC progression in patients receiving the first-generation bisphosphonate, etidronic acid, which was given in doses of 200 mg/day for 14 days, every 90 days for a total of three cycles, compared with control in patients with end-stage CKD.8 Furthermore, the findings reported by Ariyoshi *et al*,7 also in a cohort of haemodialysis patients receiving etidronate but at a higher dose of 400 mg/day for 24 weeks, are worth noting; while the authors did not report any statistical hypothesis result, a large difference in CAC of 1340 mm3 between the groups was observed at 1-year follow-up. This would support the notion that etidronic acid is capable of reducing CAC in patients with CKD. The remaining studies in this category investigated the NC-BP, alendronate, in a broader range of individuals which could explain the differences in outcomes seen. This also correlates to the difference in molecular structure between first-generation bisphosphonates and NC-BPs, with etidronate theorised to have a greater capacity for inhibition of crystallisation and thus calcification of soft tissues.23 Furthermore, a literature review showed that inhibition of soft tissue calcification by bisphosphonates is likely restricted to etidronate.24 However, the review warns that etidronate poses a risk of causing osteomalacia in patients taking it at the high doses recommended to suppress vascular calcification. Conversely, other reviews25 26 suggest that etidronate is safe if given cyclically (as was performed in the Nitta *et al*, protocol) up to a dose of 400 mg daily. Osteomalacia was not reported in the 2–3 years follow-up period.26 Continuous therapy at these doses, however, is not recommended due to intolerable gastrointestinal side effects and subsequent poor adherence. Given that etidronate displayed benefit at 200 mg daily in the Nitta *et al*, paper, we posit that this could be an optimal starting dose that also allows for up-titration in the management of vascular calcification to balance the risks and benefits of treatment. This could be an area of future research. ### RANKL inhibitors and CAC Evidence regarding the action of denosumab on CAC progression also remains conflicting, with one study reporting a statistically significant hypothesis result between intervention and control, and one study demonstrating no statistically significant difference in this review. RANKL inhibitors are comparably novel to bisphosphonates, and subsequently, research into their use is not as ubiquitous. Denosumab’s ability to inhibit vascular calcification has been proven both in vitro27 and in vivo in mice models.28 In the latter study, osteoporosis was induced by prednisone in human RANKL knock-in mice, who became responsive to denosumab, unlike their wild-type counterparts. Subsequent denosumab therapy resulted in attenuation of aortic calcium deposition up to 50% compared with the control group. In humans the data remains conflicting. An RCT conducted in haemodialysis patients by Iseri *et al*, did not demonstrate a statistically significant difference in CAC progression from baseline to follow-up at 12 months. Notably, only 18 patients reached follow-up time. Additionally, this study did not include a control group and hence did not meet the eligibility criteria for inclusion in the present review. In contrast, a larger, more recent study published by Suzuki *et al* 29 conducted over a 30-month period demonstrated the capabilities of denosumab in reducing aortic arch calcification in haemodialysis patients. Given the narrow patient selection criteria, the results may not be generalisable to a wider cohort. However, these findings corroborate those published by Chen *et al*,16 suggesting that denosumab may have selective utility to improve vascular calcification in those with end-stage CKD. ### CAC progression versus prevalence Notably, the review included only papers which investigated the impact of antiosteoporotic medications on CAC progression over time. Hence, studies evaluating the point prevalence of CAC in bisphosphonate or denosumab users were excluded. The largest study to date investigating bisphosphonate use on the prevalence of atherosclerosis is the Multi-Ethnic Study of Atherosclerosis study.30 The study included over 3000 women from diverse ethnic backgrounds and found that bisphosphonate use was associated with a reduced prevalence of overall cardiovascular calcification in women over the age of 65. However, this was not statistically significant for CAC, which is supported by our review. While men made up the bulk of participants in our review, the mean age of participants was alike, which may explain the similarity to the review’s findings. ### Antiosteoporotics and calcification in other vasculature To the authors’ knowledge, the RCT conducted by Pawade *et al* is the first of its kind to apply CAC scoring to measure aortic valve stenosis (AS) in the context of bisphosphonate and denosumab use.22 The study did not find a statistically significant result between intervention and control in either case. Other papers have reported the effect of bisphosphonates on the progression of AS but measured via aortic valve area and mean and peak gradients. Using these parameters, the literature remains conflicting, with some evidence to suggest the slowing of AS by bisphosphonates,31 32 and other evidence contradicting such an effect.33 One study reported on the review’s secondary outcome of aortic calcification.7 A statistically significant reduction in aortic calcification in the etidronic acid group compared with control was demonstrated; whilst not statistically significant in the coronary arteries, a reduction was still noted. Whilst the underlying mechanism of calcification remains analogous between the two arteries, the differences in intimal and medial histological elastic and smooth muscle fibre composition34 as well as differences in shearing forces between the vessels could theoretically result in delayed improvement in calcification measurements over the given timeframe.35 ### Strengths and limitations This review is likely to have captured most, if not all papers reporting on the topic of CAC progression in antiresorptive medication use, through its use of (1) inclusion of multiple study designs, (2) inclusion of wide study populations, that is, no limitation according to sex or presence of comorbidities and (3) a methodical search of three large databases and citation lists of relevant papers. Meta-analysis was unable to be performed in view of the small number of heterogeneous papers eligible for inclusion in the review. Furthermore, three of the four studies were shown to have a moderate risk of bias which may limit the interpretation of the data. Two studies were undertaken in patients with end-stage renal failure on dialysis, specifically, and one in patients with concomitant secondary hyperparathyroidism with normocalcaemia. Therefore, these studies may not be generalisable to the broader population, particularly in those with alternate pathological mechanisms to cause their osteoporotic bony disease and simultaneous vascular calcification. ### Future directions Further research on etidronate in renal failure patients appears warranted, given previous promising results in this demographic. Larger scale studies which aim to balance therapeutic dosing with adverse events appear worthwhile. Additionally, data pertaining to the long-term use of both first generation and nitrogen-containing bisphosphonates, and RANKL inhibitors in patients with and without renal disease would be useful to establish the temporal relationship between antiosteoporotic medications and CAC. Large-scale RCTs would be most beneficial to draw valid conclusions. ## Conclusions Given the limited number of heterogeneous studies, the present review demonstrates that there is insufficient evidence currently available to support a correlation between bisphosphonate or RANKL inhibitor use and CAC progression. Further research is warranted. ## Data availability statement Data are available on reasonable request. The authors are able to share data on reasonable request. ## Ethics statements ### Patient consent for publication Not applicable. ### Ethics approval As this paper is a systematic review, it was exempt from review by a Human Research Ethics Committee. ## Acknowledgments The authors would like to express their gratitude to the librarians at the School of Medicine and Public Health, University of Newcastle for assisting with the search and providing access to articles to aid the review process. ## Footnotes * Contributors SLS performed the search, designed the data extraction template, drafted the manuscript and managed the overall running of the project. NSM conducted scoping searches. SLS, KC and NSM were involved in study selection. NSM and KG performed data extraction. SLS, NSM and GS were involved in conceptualisation of the research question. SRG and GS reviewed and edited the manuscript and supervised the project. All authors read and approved the final manuscript before submission. GS is the guarantor of this work. * Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. * Competing interests None declared. * Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. * Provenance and peer review Not commissioned; externally peer reviewed. * Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/) This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/). ## References 1. World Health Organisation T. Cardiovascular diseases. 2022. Available: [https://www.who.int/health-topics/cardiovascular-diseases#tab=tab\_1](https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1) 2. Chua A , Blankstein R , Ko B . Coronary artery calcium in primary prevention. Aust J Gen Pract 2020;49:464–9. [doi:10.31128/AJGP-03-20-5277](http://dx.doi.org/10.31128/AJGP-03-20-5277) 3. Agatston AS , Janowitz WR , Hildner FJ , et al . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32. [doi:10.1016/0735-1097(90)90282-t](http://dx.doi.org/10.1016/0735-1097(90)90282-t) [FREE Full Text](http://bmjopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjg6IjE1LzQvODI3IjtzOjQ6ImF0b20iO3M6MjY6Ii9ibWpvcGVuLzE0LzkvZTA4NDUxNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 4. Liew G , Chow C , van Pelt N , et al . Cardiac society of Australia and New Zealand position statement: coronary artery calcium scoring. Heart Lung Circ 2017;26:1239–51. [doi:10.1016/j.hlc.2017.05.130](http://dx.doi.org/10.1016/j.hlc.2017.05.130) 5. Luckman SP , Hughes DE , Coxon FP , et al . Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581–9. [doi:10.1359/jbmr.1998.13.4.581](http://dx.doi.org/10.1359/jbmr.1998.13.4.581) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1359/jbmr.1998.13.4.581&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=9556058&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000072805200006&link_type=ISI) 6. Wang B , Wang H , Li Y , et al . Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages. Lipids Health Dis 2022;21:5. [doi:10.1186/s12944-021-01615-5](http://dx.doi.org/10.1186/s12944-021-01615-5) 7. Ariyoshi T , Eishi K , Sakamoto I , et al . Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 2006;26:215–22. [doi:10.2165/00044011-200626040-00006](http://dx.doi.org/10.2165/00044011-200626040-00006) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.2165/00044011-200626040-00006&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=17163254&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000237687200006&link_type=ISI) 8. Nitta K , Akiba T , Suzuki K , et al . Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004;44:680–8. [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1053/j.ajkd.2004.06.009&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=15384019&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000224473400012&link_type=ISI) 9. Koshiyama H , Nakamura Y , Tanaka S , et al . Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 2000;85:2793–6. [doi:10.1210/jcem.85.8.6748](http://dx.doi.org/10.1210/jcem.85.8.6748) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1210/jc.85.8.2793&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=10946883&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000165784500026&link_type=ISI) 10. Delibasi T , Emral R , Erdogan MF , et al . Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther 2007;24:319–25. [doi:10.1007/BF02849900](http://dx.doi.org/10.1007/BF02849900) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1007/BF02849900&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=17565922&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) 11. Celiloglu M , Aydin Y , Balci P , et al . The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009;16:689–93. [doi:10.1097/gme.0b013e318194cafd](http://dx.doi.org/10.1097/gme.0b013e318194cafd) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1097/gme.0b013e318194cafd&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=19240658&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) 12. Okamoto M , Yamanaka S , Yoshimoto W , et al . Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transplant 2014;2014:269613. [doi:10.1155/2014/269613](http://dx.doi.org/10.1155/2014/269613) 13. Toussaint ND , Lau KK , Strauss BJ , et al . Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010;56:57–68. [doi:10.1053/j.ajkd.2009.12.039](http://dx.doi.org/10.1053/j.ajkd.2009.12.039) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1053/j.ajkd.2009.12.039&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=20347511&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) 14. Hill JA , Goldin JG , Gjertson D , et al . Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002;9:1148–52. [doi:10.1016/s1076-6332(03)80516-0](http://dx.doi.org/10.1016/s1076-6332(03)80516-0) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1016/S1076-6332(03)80516-0&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=12385509&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000178399100005&link_type=ISI) 15. Iseri K , Watanabe M , Yoshikawa H , et al . Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res 2019;34:1014–24. [doi:10.1002/jbmr.3676](http://dx.doi.org/10.1002/jbmr.3676) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1002/jbmr.3676&link_type=DOI) 16. Chen CL , Chen NC , Wu FZ , et al . Impact of denosumab on cardiovascular calcification in patients with secondary hyperparathyroidism undergoing dialysis: a pilot study. Osteoporos Int 2020;31:1507–16. [doi:10.1007/s00198-020-05391-3](http://dx.doi.org/10.1007/s00198-020-05391-3) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1007/s00198-020-05391-3&link_type=DOI) 17. Santos LL , Cavalcanti TB , Bandeira FA . Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes 2012;5:47–54. [doi:10.4137/CMED.S10007](http://dx.doi.org/10.4137/CMED.S10007) 18. Saunders SL , Chaudhri K , McOrist NS , et al . Do bisphosphonates and RANKL inhibitors alter the progression of coronary artery calcification? A systematic review and meta-analysis protocol. BMJ Open 2022;12:e066255. [doi:10.1136/bmjopen-2022-066255](http://dx.doi.org/10.1136/bmjopen-2022-066255) 19. Sterne JA , Hernán MA , Reeves BC , et al . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. [doi:10.1136/bmj.i4919](http://dx.doi.org/10.1136/bmj.i4919) 20. Methods Bias C. RoB 2: A Revised Cochrane Risk-of-Bias Tool for Randomized Trials: Cochrane. 2022. Available: [https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials](https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials) 21. Higgins JP , Green S . What Is Heterogeneity? Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0: The Cochrane Collaboration. 2011. 22. Pawade TA , Doris MK , Bing R , et al . Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial. Circulation 2021;143:2418–27. [doi:10.1161/CIRCULATIONAHA.121.053708](http://dx.doi.org/10.1161/CIRCULATIONAHA.121.053708) 23. Yavropoulou MP , Pikilidou M , Yovos JG . Anti-osteoporotic drugs and vascular calcification: the bidirectional calcium traffic. J Vasc Res 2014;51:37–49. [doi:10.1159/000355204](http://dx.doi.org/10.1159/000355204) 24. Hildebrand S , Cunningham J . Is there a role for bisphosphonates in vascular calcification in chronic kidney disease? Bone 2021;142. [doi:10.1016/j.bone.2020.115751](http://dx.doi.org/10.1016/j.bone.2020.115751) 25. Stevenson M , Lloyd Jones M , De Nigris E , et al . n.d. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1–160. [doi:10.3310/hta9220](http://dx.doi.org/10.3310/hta9220) 26. Kherani RB , Papaioannou A , Adachi JD . Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf 2002;25:781–90. [doi:10.2165/00002018-200225110-00003](http://dx.doi.org/10.2165/00002018-200225110-00003) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.2165/00002018-200225110-00003&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=12222989&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) 27. Lerman DA , Prasad S , Alotti N . Denosumab could be a potential inhibitor of valvular interstitial cells calcification in vitro Int J Cardiovasc Res 2016;5. [doi:10.4172/2324-8602.1000249](http://dx.doi.org/10.4172/2324-8602.1000249) 28. Helas S , Goettsch C , Schoppet M , et al . Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009;175:473–8. [doi:10.2353/ajpath.2009.080957](http://dx.doi.org/10.2353/ajpath.2009.080957) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.2353/ajpath.2009.080957&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=19590040&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000268508500002&link_type=ISI) 29. Suzuki S , Suzuki M , Hanafusa N , et al . Denosumab recovers aortic arch calcification during long-term hemodialysis. Kidney Int Rep 2021;6:605–12. [doi:10.1016/j.ekir.2020.12.002](http://dx.doi.org/10.1016/j.ekir.2020.12.002) 30. Elmariah S , Delaney JAC , O’Brien KD , et al . Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2010;56:1752–9. [doi:10.1016/j.jacc.2010.05.050](http://dx.doi.org/10.1016/j.jacc.2010.05.050) [FREE Full Text](http://bmjopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjEwOiI1Ni8yMS8xNzUyIjtzOjQ6ImF0b20iO3M6MjY6Ii9ibWpvcGVuLzE0LzkvZTA4NDUxNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 31. Alishiri G , Heshmat-Ghahdarijani K , Hashemi M , et al . Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study. J Res Med Sci 2020;25:65. [doi:10.4103/jrms.JRMS\_408\_20](http://dx.doi.org/10.4103/jrms.JRMS_408_20) 32. Sterbakova G , Vyskocil V , Linhartova K . Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study. Cardiology 2010;117:184–9. [doi:10.1159/000321418](http://dx.doi.org/10.1159/000321418) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1159/000321418&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=21079402&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000286805500006&link_type=ISI) 33. Aksoy O , Cam A , Goel SS , et al . Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol 2012;59:1452–9. [doi:10.1016/j.jacc.2012.01.024](http://dx.doi.org/10.1016/j.jacc.2012.01.024) [FREE Full Text](http://bmjopen.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjEwOiI1OS8xNi8xNDUyIjtzOjQ6ImF0b20iO3M6MjY6Ii9ibWpvcGVuLzE0LzkvZTA4NDUxNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 34. Homma S , Troxclair DA , Zieske AW , et al . Histological topographical comparisons of atherosclerosis progression in juveniles and young adults. Atherosclerosis 2008;197:791–8. [doi:10.1016/j.atherosclerosis.2007.07.027](http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.027) [CrossRef](http://bmjopen.bmj.com/lookup/external-ref?access_num=10.1016/j.atherosclerosis.2007.07.027&link_type=DOI) [PubMed](http://bmjopen.bmj.com/lookup/external-ref?access_num=17869259&link_type=MED&atom=%2Fbmjopen%2F14%2F9%2Fe084516.atom) [Web of Science](http://bmjopen.bmj.com/lookup/external-ref?access_num=000255454900039&link_type=ISI) 35. Roux E , Bougaran P , Dufourcq P , et al . Fluid shear stress sensing by the endothelial layer. Front Physiol 2020;11:861. [doi:10.3389/fphys.2020.00861](http://dx.doi.org/10.3389/fphys.2020.00861)